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Abstract We have used the yeast two-hybrid system to screen 
for proteins that interact with the carboxy-terminal domain of 
APP. Six different clones were isolated and sequence analyses 
revealed that they encoded domains of a previously described 
neuronal protein Fe65, a homologue of Fe65 and a homologue of 
protein X11. All of these proteins contain one or more 
phosphotyrosine binding (PTB) domains. PTB domain proteins 
bind to the sequence Asn-Pro-X-Tyr when the Tyr is phosphory- 
lated and are believed to function in signal transduction. APP 
contains such a motif. These results are consistent with a role for 
APP in signal transduction mechanisms. 
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1. Introduction 
Deposits of P-amyloid in neuritic plaques and blood vessel 
walls are a principal pathological feature in the brains of 
patients with Alzheimer’s disease. These amyloid deposits 
contain the 3943 amino acid P-amyloid peptide which is 
derived by proteolytic cleavage from its much larger precur- 
sor, the amyloid precursor protein (APP). P-amyloid is a nor- 
mal physiological product of APP metabolism. However, it is 
thought that aberrant processing of APP to produce either 
increased amounts of P-amyloid or longer (42/43 amino 
acid) and hence more amyloidogenic P-amyloid isoforms, is 
a primary pathogenic event leading to amyloid deposition in 
Alzheimer’s disease (see [l-3] for reviews). 
APP gene mRNA transcripts are alternatively spliced so as 
to generate a number of different APP molecules; the princi- 
pal isoforms comprising 69.5, 751 and 770 amino acids. The 
longer isoforms contain a domain that displays homology to 
the Kunitz class of protease inhibitors [4]. APP695 is the pre- 
dominant isoform found in brain. 
APP is a membrane-spanning protein which crosses the 
plasma membrane once and contains a large extracellular do- 
main (which in APP751 and APP770 contains the Kunitz 
protease inhibitor domain) and a smaller 47 amino acid in- 
tracellular domain. P-amyloid is derived from sequences con- 
tained within and just external to the membrane spanning 
domain (see [l-3] for reviews). 
Although secreted extracellular domains of APP containing 
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the Kunitz protease inhibitor domain may act as extracellular 
serine protease inhibitors, [5,6] the function of membrane- 
bound APP is not fully understood. However, APP has 
some structural features of cell surface receptors [7] and the 
intracellular domain of APP has been shown to bind G, [8] 
which suggests that it may be involved in signal transduction 
processes. In common with a number of cell surface receptors, 
membrane-bound APP has been shown to be re-internalised 
into lysosomes where intact P-amyloid containing fragments 
are produced and this is believed to be one route for the 
production of P-amyloid [9-121. The carboxy terminal intra- 
cellular domain of APP contains the motif Asn-Pro-Thr-Tyr 
which is a sequence known to mediate re-internalisation via 
clathrin-coated pits [13]. If the tyrosine in this sequence is 
phosphorylated, then this motif is also a consensus sequence 
for binding to phosphotyrosine binding (PTB) domains [14 
161 (and see [17] for review). To understand further the func- 
tion of APP and the mechanism(s) of P-amyloid production, 
we have used the yeast two-hybrid system to identify proteins 
that interact with the intracellular carboxy-terminal portion of 
APP. Here we demonstrate that this domain of APP interacts 
with a number of PTB domain containing proteins. 
2. Materials and methods 
To generate a GAL-4 DNA binding domain-APP fusion ‘bait’ plas- 
mid, sequences encoding the intracellular carboxy-terminal 47 amino 
acids of APP (APPc) were amplified by PCR and cloned into the 
GAL-4 DNA binding domain yeast shuttle vector pY1 [18] so as to 
produce pY1 APPc. Clones were sequenced to check that no PCR 
errors had been introduced and that APP sequences were in-frame 
with GAL-4 encoding sequences. pY 1APPc was used to screen a hu- 
man brain cDNA library containing the GAL-4 transactivation do- 
main in pGADl0 (Clontech) by co-transformation of both plasmids 
into yeast Yl90. Yeast transformations were performed using lithium 
acetate/heat shock as described (Clontech). Y 190 possesses both IacZ 
and His GAL reporters. Transformants were grown for 8 days at 
30°C on synthetic selection medium lacking tryptophan, leucine and 
histidine and containing 25 mM 3-amino triazole. Large (> 2 mm) 
colonies surviving selection were picked and assayed for B-galactosi- 
dase activity using a freeze-fracture assay. Plasmids from colonies 
positive on both the nutrient (His) and B-galactosidase assays were 
rescued into Escherichia coli HBlOl. To check that positive plasmids 
only transactivated in the presence of pY IAPPc, yeast Yl90 were re- 
transformed with the candidate plasmids either alone, or with pY 1 or 
pLAM5’ (Clontech) that contains the GAL-4 DNA binding domain 
fused to an extraneous fragment of laminin and colonies again as- 
sayed for B-galactosidase activity. Positive controls included transfor- 
mation of Yl90 with pCL1 (that contains full-length GAL-4) and co- 
transformation with pVA3 and pTD1 (that contain respectively the 
GAL-4 DNA binding domain fused to p53 encoding sequences, and 
GAL-4 transactivation domain fused to SV40 large T antigen encod- 
ing sequences). pCL1, pVA3 and pTD1 were obtained from Clontech. 
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Plasmids from positive clones which transactivated only in the pres- 
ence of pYlAPPc were sequenced and homology searches performed 
using the BLAST network service. 
3. Results and discussion 
Approximately 10” independent library colonies were 
screened with pYlAPPc using the yeast two-hybrid system 
and six positive clones identified. Analyses of the open reading 
frames of these clones revealed that threecontained identical 
inserts which encoded the carboxy-terminal 422 amino acids 
of the human homologue (HFe65) of a previously described 
rat neuronal protein, Fe65 [19]. A fourth clone encoded the 
carboxy-terminal 648 amino acids of HFe6.5. The fifth clone 
contained sequences that encoded an open reading frame of 
150 amino acids that were 64% identical to HFe65 at the 
amino acid sequence level. This suggests that clone 5 might 
contain a homologue of HFe65 (HFe65-like) and that there 
may be a family of Fe65 proteins. No in-frame start codon 
with surrounding Kozak sequence or stop codon were present 
in the clone 5 insert which indicates that it lacks both the 
amino- and carboxy-terminal encoding DNA sequences of 
this protein. The sixth clone contained an open reading frame 
A 
Fe65/rat (NJ 
Fe65/human (N) 
Fe65/rat (NJ 
Fe65/human (NJ 
Fe65/rat (N) 
Fe65/human (NJ 
B 
Fe65/rat (C) 
Fe65/human (Cl 
Fe65-like 
Fe65/rat (Cl 
Fe65/human (Cl 
Fe65-like 
Fe65/rat (Cl 
Fe65/human (Cl 
Fe65-like 
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encoding 441 amino acids that bore greatest similarity to a 
mouse homologue of protein X11 [20] (99% homology at the 
amino acid sequence level) but which displayed less homology 
to human protein Xl1 [21] (83% homology at the amino acid 
sequence level). Further searches revealed that overlapping 
but identical sequences to the clone 6 insert had previously 
been deposited in the database (Accession numbers R89683, 
Rl3101, R18654 and T16098). Clone 6 contains an in-frame 
stop codon but no in-frame ATG with surrounding Kozak 
sequence and so may well code for a truncated carboxy-ter- 
minal fragment. To simplify the terminology in this report, we 
have termed the protein encoded by clone 6, protein X1 l-like. 
Analyses of the proteins encoded by the six clones revealed 
that they all contain at least one phosphotyrosine binding 
(PTB) domain. The HFe65 clones contain two PTB domains; 
the HFe65-like clone contains one PTB domain (indeed, the 
amino acid sequences encoded in the clone represent a single 
PTB domain); and the protein X11-like clone contains one 
PTB domain. The PTB domains of HFe65, HFe65-like and 
protein X11-like are shown and aligned in Figs. 1 and 2. It 
has previously been noted that both Fe65 and protein Xl1 
have PTB domains [22,23]. 
Fiore et al. [23] have shown that the rat Fe65 PTB domains 
143 NPGIKCFAVRSLGWVEMTEEELAPGRSSVAVNNCIRQLSYHKNNLHDPMS 
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IIIIIIIIIIIIIIIlIIIIIIII I 1IIIIIl 1111111111111111111 
GGWGEGKDLLLQLEDETLKLVEPQSQALLHAQPIISIRVWGVGRDSGRERDFAY 
VARDKLTQMLKCHVFRCEAPAKNIATSLHEICSKIMSERRNA 288 x04689 
lIIIIIIlIIIIIIIIIIIIIIIIlIIIIIIIIIII IIIII 
VARDKLTQMLKCHVFRCEAPAKNIATSLHEICSKIMAERRNA 
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IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
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III III I III II IIII I I I I II I I I I 
TELVQKFHVQYLGMLPVDKPVGMDILNSAIENLMTSSNKEDWLSVNMNVA 
PATLTIL-HQQTEAVLGECRVRFLSFLSFLAVGRD~TFAFI~GPASFCC~FWC 
Illllll IIIIIIIIIIIIIIIIlIIlllllllllllllllllllllllllll 
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II I I II IIIIIIIII II IIIIIIIII I I II III 
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I I I I I I I I I I I I I I I I I I I I I I I I I 
EPNAASLSEAVQAACMLRYQKCLDA 
I I I I IIIIIIIIIIIIIIIl I 
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Fig. 1. Alignments of the PTB domain amino acid sequences from rat and human Fe65 and human Fe65-like protein. A: Alignment of the 
amino-terminal (N) PTB domains of human and rat Pe65. B: Alignment of the carboxy-terminal (C) PTB domains of rat and human Fe65 
with the PTB domain identified in human Fe654ke protein. Dashed line indicates a gap in the alignment. The accession numbers for the indi- 
vidual proteins are listed at the end of relevant sequences. 
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X11-like LIDGIIFAANYLGSTQLLSERNPSKNIRMMQAQEAVSRVKRMQKAAKIKK 
IIIlIIIlIIIIIIIIIlIII IIIIIIIIIIIII IIIIIIIIIIIIII 
Xll/mouse 298 LIDGIIFAANYLGSTQLLSERTPSKNIRMMQAQEAASRVKRMQ~KIKK 
I I I I I I I I I I I I I I I I I I I IIIII IIIIIIII II I II II I 
x11 326 LIDGIIFAANYLGSTQLLSDKTPSKNVRMMQAQEAVSRIKMAQKLAKSRK 
X11-like KANSEGDAQTLTEVDLFISTQRIKVLNADTQETMMDHALRTISYIADIGNIWLM 
IIIIIIIIIIIIIIIIIIIllllllllllllllIIIIIIIIIIIIIIIIIIIIII 
Xll/mouse KANSEGDAQTLTEVDLFISTQRIKVLNADTQETMMDHALRTISYIADIGNIWLM 
II II I IIIIIII IIlIIIIIlIIIIIIIII IIIIIIIlIIIIIIIII 
x11 KA-PEGESQPMTEVDLFILTQRIKVLNADTQETMMDHPLRIGNIWLM 
X11-like ARRRMPRSASQDCIETTPGAQEGKKQYKMICHVFESEDAQLIAQSIGQAFSVAYQ 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Xll/mouse ARRRMPRSASQDCIETTPGAQEGKKQYKMICHVFESEDAQLIAQSIGQAFSVAYQ 
III1 III II I I II IIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
x11 ARRRIPRSNSQENVEASHPSQDGKRQYKMICHVFESEDAQLIAQSIGQAFSVAYQ 
X11-like EFLRA 
I I I I I 
Xll/mouse EFLRA 462 L34676 
I I I I I 
x11 EFLRA 489 LO4953 
Fig. 2. Alignments of the PTB domain sectuences from the amino acid sequences of the mouse and human versions of the Xl 1 protein plus the 
PT-B domain sequence of the human Xl I-iike protein. 
interact with the carboxy-terminus of APP in the yeast two- mains, PTB domains appear to bind tyrosine phosphorylated 
hybrid system and in co-precipitation experiments with Glu- proteins although SH2 and PTB domains are structurally un- 
tathione-S transferase-Fe65 fusion proteins. However, their related. It is believed that PTB domains impart on proteins an 
approach involved utilising Fe65 sequences as ‘bait’ to screen ability to bind the sequence motif Asn-Pro-X-Tyr when the 
a library rather than APP sequences. Our findings that the Tyr is phosphorylated and that PTB domain containing pro- 
intracellular domain of APP interacts with human Fe65 teins function in mechanisms for transducing signals from the 
when APP is used as ‘bait’ thus confirms and extends their cell surface [15,17,24,25]. The intracellular portion of APP 
findings. used here as bait contains one Asn-Pro-X-Tyr motif. 
In addition, we demonstrate that two other PTB domain 
proteins, HFe65-like (a homologue of Fe65) and protein Xl l- 
like (a homologue of protein Xl l), all interact with the intra- 
cellular carboxy-terminal domain of APP in the yeast two- 
hybrid system. Protein Xl 1 was originally identified as a can- 
didate for the Friedreich’s ataxia disease gene [21]. A mouse 
homologue of protein X11 has been cloned [20] and the se- 
quences we have isolated for protein Xl l-like protein display 
high and greater homology to this murine homologue than to 
protein X11 (protein X11-like is 99% identical to the mouse 
protein X11 but 83% identical to human protein X11) which 
suggests that there might be a family of these proteins. Thus 
both the mouse and human genomes contain a protein Xl l- 
like gene. In situ hybridisation studies with mouse protein 
Xl l-like probes reveal that its transcripts are widely expressed 
throughout the nervous system including the cortex and hip- 
pocampus, two of the regions affected in Alzheimer’s disease 
Pll. 
APP has previously been shown to interact with G, and to 
have cell signalling functions in vitro via its carboxy-terminal 
sequences [8,26]. In addition, APP has recently been reported 
to interact with N-Pak, a neural-specific p21 activated kinase 
[27]. Such observations suggest that APP may have a role in 
signal transduction. In this context, it is striking that we find 
that three different PTB domain containing proteins will in- 
teract with APP in the yeast two-hybrid system; proteins con- 
taining PTB domains are believed to function in signal trans- 
duction [17]. Thus our findings further implicate APP (either 
directly or indirectly) in such cell signalling mechanisms. 
The Fe65-like sequences we have isolated encode for 150 
amino acids and this appears to essentially comprise a single 
PTB domain (see [22] for alignment of some PTB domains). 
Thus, it appears that an isolated PTB domain from Fe65-like 
protein is sufficient for binding to the carboxy-terminal intra- 
cellular domain of APP. 
The Asn-Pro-X-Tyr motif is also believed to mediate re- 
internalisation of receptors from the cell surface via clathrin- 
coated pits [13]. Such a re-internalisation of APP into lyso- 
somes is one route for the generation of secreted P-amyloid 
and mutation of the Asn-Pro-X-Tyr motif is inhibitory to p- 
amyloid production [12]. In this respect, it will be interesting 
to determine how expression of the three PTB domain pro- 
teins described here influence APP processing and b-amyloid 
production. Such studies are currently underway in this lab- 
oratory. 
The PTB domain was originally identified in the Src homol- 
ogy 2 (SH2) containing protein She [24,25]. Like SH2 do- 
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